Non-alcoholic fatty liver disease: An expanded review

World Journal of Hepatology

Volumn 9, Issue 16, 2017, Pages 715-732

  Benedict, Mark ^a   Zhang, Xuchen ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatocellular carcinoma; ; Metabolic syndrome; Non alcoholic fatty liver disease; Steatohepatitis; Steatosis

Indexed keywords

EID: 85020256351     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v9.i16.715     Document Type: Review

References (191)

1. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis 2016; 20: 205-214 [PMID: 27063264 DOI: 10.1016/j.cld.2015.10.001]
2. Kanwar P, Kowdley KV. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clin Liver Dis 2016; 20: 225-243 [PMID: 27063266 DOI: 10.1016/j.cld.2015.10.002]
3. Calzadilla Bertot L, Adams LA. The Natural Course of NonAlcoholic Fatty Liver Disease. Int J Mol Sci 2016; 17: pii: E774 [PMID: 27213358 DOI: 10.3390/ijms17050774]
4. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80 [PMID: 2295475]
5. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669 [PMID: 10051466 DOI: 10.1002/hep.510290347]
6. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689-692 [PMID: 11003611 DOI: 10.1053/ jhep.2000.17894]
7. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719 [PMID: 7489979]
8. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, Srishord M. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012; 91: 319-327 [PMID: 23117851 DOI: 10.1097/MD.0b013e3182779d49]
9. Patel V, Sanyal AJ, Sterling R. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016; 20: 277-292 [PMID: 27063269 DOI: 10.1016/j.cld.2015.10.006]
10. Federico A, Dallio M, Masarone M, Persico M, Loguercio C. The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction. Eur Rev Med Pharmacol Sci 2016; 20: 4731-4741 [PMID: 27906428]
11. Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, Targher G. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis 2015; 47: 997-1006 [PMID: 26454786 DOI: 10.1016/j.dld.2015.08.004]
12. Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol 2014; 60: 1040-1045 [PMID: 24445219 DOI: 10.1016/j.jhep.2014.01.009]
13. Kalia HS, Gaglio PJ. The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities. Clin Liver Dis 2016; 20: 215-224 [PMID: 27063265 DOI: 10.1016/j.cld.2015.10.005]
14. Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50: 797-804 [PMID: 19231016 DOI: 10.1016/j.jhep.2008.11.017]
15. Satapathy SK, Sanyal AJ. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015; 35: 221-235 [PMID: 26378640 DOI: 10.1055/s-0035-1562943]
16. Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol 2013; 167: 1109-1117 [PMID: 23141876 DOI: 10.1016/j.ijcard.2012.09.085]
17. Goyal NP, Schwimmer JB. The Progression and Natural History of Pediatric Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016; 20: 325-338 [PMID: 27063272 DOI: 10.1016/j.cld.2015.10.003]
18. Brumbaugh DE, Tearse P, Cree-Green M, Fenton LZ, Brown M, Scherzinger A, Reynolds R, Alston M, Hoffman C, Pan Z, Friedman JE, Barbour LA. Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes. J Pediatr 2013; 162: 930-936.e1 [PMID: 23260099 DOI: 10.1016/ j.jpeds.2012.11.017]
19. Patel KR, White FV, Deutsch GH. Hepatic steatosis is prevalent in stillborns delivered to women with diabetes mellitus. J Pediatr Gastroenterol Nutr 2015; 60: 152-158 [PMID: 25079479 DOI: 10.1097/mpg.0000000000000520]
20. Nobili V, Bedogni G, Alisi A, Pietrobattista A, Alterio A, Tiribelli C, Agostoni C. A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease. Arch Dis Child 2009; 94: 801-805 [PMID: 19556219 DOI: 10.1136/adc.2009.159566]
21. Schwimmer JB. Clinical advances in pediatric nonalcoholic fatty liver disease. Hepatology 2016; 63: 1718-1725 [PMID: 27100147 DOI: 10.1002/hep.28441]
22. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-1393 [PMID: 17015527 DOI: 10.1542/ peds.2006-1212]
23. Nobili V, Alisi A, Grimaldi C, Liccardo D, Francalanci P, Monti L, Castellano A, de Ville de Goyet J. Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity? Pediatr Obes 2014; 9: e99-e102 [PMID: 24302697 DOI: 10.1111/j.2047-6310.2013.00209.x]
24. Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol 2002; 97: 2460-2462 [PMID: 12358273 DOI: 10.1111/j.1572-0241.2002.06003.x]
25. Andersen CJ, Fernandez ML. Dietary strategies to reduce metabolic syndrome. Rev Endocr Metab Disord 2013; 14: 241-254 [PMID: 23943309 DOI: 10.1007/s11154-013-9251-y]
26. Godos J, Federico A, Dallio M, Scazzina F. Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. Int JFoodSci Nutr 2017; 68: 18-27 [PMID: 27484357]
27. Hamabe A, Uto H, Imamura Y, Kusano K, Mawatari S, Kumagai K, Kure T, Tamai T, Moriuchi A, Sakiyama T, Oketani M, Ido A, Tsubouchi H. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J Gastroenterol 2011; 46: 769-778 [PMID: 21302121 DOI: 10.1007/s00535-011-0376-z]
28. Targher G, Alberiche M, Zenere MB, Bonadonna RC, Muggeo M, Bonora E. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 3619-3624 [PMID: 9360516 DOI: 10.1210/ jcem. 82.11.4351]
29. Rönnemaa T, Rönnemaa EM, Puukka P, Pyörälä K, Laakso M. Smoking is independently associated with high plasma insulin levels in nondiabetic men. Diabetes Care 1996; 19: 1229-1232 [PMID: 8908385]
30. Carnethon MR, Fortmann SP, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE. Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2003; 158: 1058-1067 [PMID: 14630601]
31. Weitzman M, Cook S, Auinger P, Florin TA, Daniels S, Nguyen M, Winickoff JP. Tobacco smoke exposure is associated with the metabolic syndrome in adolescents. Circulation 2005; 112: 862-869 [PMID: 16061737 DOI: 10.1161/circulationaha.104.520650]
32. Marchesini G, Day C.P, Dufour JF, Canbay A, Nobili V, Ratziu V, Tilg H, Roden M, Gastaldelli A, Yki-Järvinen H, Schick F, Vettor R, Frühbeck G, Mathus-Vliegen L. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004]
33. Zelber-Sagi S, Godos J, Salomone F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therap Adv Gastroenterol 2016; 9: 392-407 [PMID: 27134667 DOI: 10.1177/1756283 x16638830]
34. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and metaanalysis. J Hepatol 2012; 57: 157-166 [PMID: 22414768 DOI: 10.1016/j.jhep.2012.02.023]
35. Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T, Takano Y, Ueno T, Koga H, George J, Shiba N, Torimura T. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol 2017; 66: 142-152 [PMID: 27639843 DOI: 10.1016/j.jhep.2016.08.023]
36. Macut D, Tziomalos K, Božić-Antić I, Bjekić-Macut J, Katsikis I, Papadakis E, Andrić Z, Panidis D. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod 2016; 31: 1347-1353 [PMID: 27076501 DOI: 10.1093/humrep/dew076]
37. Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2014; 81: 523-528 [PMID: 24256515 DOI: 10.1111/cen.12369]
38. Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, Tzavara I. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 2010; 25: 212-220 [PMID: 19887498 DOI: 10.1093/humrep/dep380]
39. Markou A, Androulakis II, Mourmouris C, Tsikkini A, Samara C, Sougioultzis S, Piaditis G, Kaltsas G. Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertil Steril 2010; 93: 1220-1226 [PMID: 19171337 DOI: 10.1016/ j.fertnstert.2008.12.008]
40. Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 2010; 26: 39-46 [PMID: 20001571 DOI: 10.3109/09513590903184084]
41. Paschetta E, Belci P, Alisi A, Liccardo D, Cutrera R, Musso G, Nobili V. OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Inflamm 2015; 2015: 815721 [PMID: 25873773 DOI: 10.1155/2015/815721]
42. Tanné F, Gagnadoux F, Chazouillères O, Fleury B, Wendum D, Lasnier E, Lebeau B, Poupon R, Serfaty L. Chronic liver injury during obstructive sleep apnea. Hepatology 2005; 41: 1290-1296 [PMID: 15915459 DOI: 10.1002/hep.20725]
43. Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 2008; 47: 1916-1923 [PMID: 18433022 DOI: 10.1002/hep.22241]
44. Aron-Wisnewsky J, Minville C, Tordjman J, Lévy P, Bouillot JL, Basdevant A, Bedossa P, Clément K, Pépin JL. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol 2012; 56: 225-233 [PMID: 21703181 DOI: 10.1016/j.jhep.2011.04.022]
45. Mishra P, Nugent C, Afendy A, Bai C, Bhatia P, Afendy M, Fang Y, Elariny H, Goodman Z, Younossi ZM. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int 2008; 28: 1080-1086 [PMID: 18647236 DOI: 10.1111/j.1478-3231.2008.01822.x]
46. Daltro C, Cotrim HP, Alves E, de Freitas LA, Araújo L, Boente L, Leal R, Portugal T. Nonalcoholic fatty liver disease associated with obstructive sleep apnea: just a coincidence? Obes Surg 2010; 20: 1536-1543 [PMID: 20556538 DOI: 10.1007/s11695-010-0212-1]
47. Kallwitz ER, Herdegen J, Madura J, Jakate S, Cotler SJ. Liver enzymes and histology in obese patients with obstructive sleep apnea. J Clin Gastroenterol 2007; 41: 918-921 [PMID: 18090161 DOI: 10.1097/01.mcg.0000225692.62121.55]
48. Polotsky VY, Patil SP, Savransky V, Laffan A, Fonti S, Frame LA, Steele KE, Schweizter MA, Clark JM, Torbenson MS, Schwartz AR. Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med 2009; 179: 228-234 [PMID: 18990675 DOI: 10.1164/rccm.200804-608OC]
49. Anstee QM, Day CP. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Semin Liver Dis 2015; 35: 270-290 [PMID: 26378644 DOI: 10.1055/s-0035-1562947]
50. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 2957-2961 [PMID: 11693332 DOI: 10.1111/j.1572-0241. 2001.04667.x]
51. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000; 108: 9-13 [PMID: 11059435]
52. Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, Schork NJ, Shiehmorteza M, Yokoo T, Chavez A, Middleton MS, Sirlin CB. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009; 136: 1585-1592 [PMID: 19208353 DOI: 10.1053/j.gastro.2009.01.050]
53. Makkonen J, Pietiläinen KH, Rissanen A, Kaprio J, Yki-Järvinen H. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J Hepatol 2009; 50: 1035-1042 [PMID: 19303161 DOI: 10.1016/j.jhep.2008.12.025]
54. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]
55. Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004; 99: 292-298 [PMID: 15046220]
56. Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009; 49: 791-801 [PMID: 19105205 DOI: 10.1002/ hep.22726]
57. Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012; 55: 769-780 [PMID: 21987488 DOI: 10.1002/hep.24726]
58. Ravi Kanth VV, Sasikala M, Sharma M, Rao PN, Reddy DN. Genetics of non-alcoholic fatty liver disease: From susceptibility and nutrient interactions to management. World J Hepatol 2016; 8: 827-837 [PMID: 27458502 DOI: 10.4254/wjh.v8.i20.827]
59. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465 [PMID: 18820647 DOI: 10.1038/ ng.257]
60. Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kokubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F, Okanoue T. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 2012; 7: e38322 [PMID: 22719876 DOI: 10.1371/journal. pone.0038322]
61. Akuta N, Kawamura Y, Arase Y, Suzuki F, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Ikeda K, Kumada H. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan. Gut Liver 2016; 10: 437-445 [PMID: 26610348 DOI: 10.5009/gnl15163]
62. Kanth VV, Sasikala M, Rao PN, Steffie Avanthi U, Rao KR, Nageshwar Reddy D. Pooled genetic analysis in ultrasound measured non-alcoholic fatty liver disease in Indian subjects: A pilot study. World J Hepatol 2014; 6: 435-442 [PMID: 25018854 DOI: 10.4254/wjh.v6.i6.435]
63. Bhatt SP, Nigam P, Misra A, Guleria R, Pandey RM, Pasha MA. Genetic variation in the patatin-like phospholipase domain- containing protein-3 (PNPLA-3) gene in Asian Indians with nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2013; 11: 329-335 [PMID: 23734760 DOI: 10.1089/met.2012.0064]
64. Zhang Y, Cai W, Song J, Miao L, Zhang B, Xu Q, Zhang L, Yao H. Association between the PNPLA3 I148M polymorphism and non-alcoholic fatty liver disease in the Uygur and Han ethnic groups of northwestern China. PLoS One 2014; 9: e108381 [PMID: 25290313 DOI: 10.1371/journal.pone.0108381]
65. Peng XE, Wu YL, Lin SW, Lu QQ, Hu ZJ, Lin X. Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population. PLoS One 2012; 7: e50256 [PMID: 23226254 DOI: 10.1371/journal.pone.0050256]
66. Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, Waljee AK. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 2014; 109: 325-334 [PMID: 24445574 DOI: 10.1038/ajg.2013.476]
67. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894 [PMID: 21381068 DOI: 10.1002/hep.24283]
68. Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. Sci Rep 2015; 5: 9284 [PMID: 25791171 DOI: 10.103 8/srep09284]
69. Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, Cui J, Taylor KD, Wilson L, Cummings OW, Chen YD, Rotter JI. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology 2010; 139: 1567-1576, 1576.e1-6 [PMID: 20708005 DOI: 10.1053/j.gastro.2010.07.057]
70. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjærg-Hansen A, Vogt TF, Hobbs HH, Cohen JC. Exome- wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46: 352-356 [PMID: 24531328 DOI: 10.1038/ng.2901]
71. Mahdessian H, Taxiarchis A, Popov S, Silveira A, Franco-Cereceda A, Hamsten A, Eriksson P, van't Hooft F. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci USA 2014; 111: 8913-8918 [PMID: 24927523 DOI: 10.1073/pnas.1323785111]
72. Khatib MN, Gaidhane S, Gaidhane AM, Simkhada P, Zahiruddin QS. Ghrelin O Acyl Transferase (GOAT) as a Novel Metabolic Regulatory Enzyme. J Clin Diagn Res 2015; 9: LE01-LE05 [PMID: 25859472 DOI: 10.7860/JCDR/2015/9787.5514]
73. Townsend SA, Newsome PN. Non-alcoholic fatty liver disease in 2016. Br Med Bull 2016; 119: 143-156 [PMID: 27543499 DOI: 10.1093/bmb/ldw031]
74. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-1048 [PMID: 26823198 DOI: 10.1016/j.metabol. 2015.12.012]
75. Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014; 15: 8591-8638 [PMID: 24830559 DOI: 10.3390/ ijms15058591]
76. Petta S, Valenti L, Bugianesi E, Targher G, Bellentani S, Bonino F. A "systems medicine" approach to the study of non-alcoholic fatty liver disease. Dig Liver Dis 2016; 48: 333-342 [PMID: 26698409 DOI: 10.1016/j.dld.2015.10.027]
77. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16: 1941-1951 [PMID: 20370677]
78. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-377 [PMID: 18401346 DOI: 10.1038/nrm2391]
79. Cusi K. Role of insulin resistance and lipotoxicity in nonalcoholic steatohepatitis. Clin Liver Dis 2009; 13: 545-563 [PMID: 19818304 DOI: 10.1016/j.cld.2009.07.009]
80. Federico A, Dallio M, Godos J, Loguercio C, Salomone F. Targeting gut-liver axis for the treatment of nonalcoholic steato- hepatitis: translational and clinical evidence. Transi Res 2016; 167: 116-124 [PMID: 26318867 DOI: 10.1016/j.trsl.2015.08.002]
81. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420-1427 [PMID: 20486907 DOI: 10.1111/ j.1600-6143.2010.03126.x]
82. Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009; 15: 1814-1820 [PMID: 19938128 DOI: 10.1002/lt.21927]
83. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int 2005; 18: 461-466 [PMID: 15773968 DOI: 10.1111/j.1432-2277.2004.00067.x]
84. Lane JT, Dagogo-Jack S. Approach to the patient with new-onset diabetes after transplant (NODAT). J Clin Endocrinol Metab 2011; 96: 3289-3297 [PMID: 22058376 DOI: 10.1210/jc.2011-0657]
85. Gitto S, Villa E. Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome after Liver Transplant. Int J Mol Sci 2016; 17: 490 [PMID: 27049380 DOI: 10.3390/ijms17040490]
86. Sprinzl MF, Weinmann A, Lohse N, Tönissen H, Koch S, Schattenberg J, Hoppe-Lotichius M, Zimmermann T, Galle PR, Hansen T, Otto G, Schuchmann M. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. Transpl Int 2013; 26: 67-74 [PMID: 23126674 DOI: 10.1111/j.1432-2277.2012.01576.x]
87. Mikolasevic I, Orlic L, Hrstic I, Milic S. Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation. Hepatol Res 2016; 46: 841-852 [PMID: 26713425 DOI: 10.1111/hepr. 12642]
88. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-353 [PMID: 21520200 DOI: 10.1002/hep.24376]
89. Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014; 147: 754-764 [PMID: 25109884 DOI: 10.1053/j.gastro.2014.07.056]
90. Bedossa P. Histological Assessment of NAFLD. Dig Dis Sci 2016; 61: 1348-1355 [PMID: 26874689 DOI: 10.1007/s10620-016-4062-0]
91. Burt AD, Lackner C, Tiniakos DG. Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification. Semin Liver Dis 2015; 35: 207-220 [PMID: 26378639 DOI: 10.1055/ s-0035-1562942]
92. Yip WW, Burt AD. Alcoholic liver disease. Semin Diagn Pathol 2006; 23: 149-160 [PMID: 17355088 DOI: 10.1053/j.semdp. 2006.11.002]
93. Sahini N, Borlak J. Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes. Prog Lipid Res 2014; 54: 86-112 [PMID: 24607340 DOI: 10.1016/j.plipres. 2014.02.002]
94. Smagris E, BasuRay S, Li J, Huang Y, Lai KM, Gromada J, Cohen JC, Hobbs HH. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 2015; 61: 108-118 [PMID: 24917523 DOI: 10.1002/hep.27242]
95. Singhi AD, Jain D, Kakar S, Wu TT, Yeh MM, Torbenson M. Reticulin loss in benign fatty liver: an important diagnostic pitfall when considering a diagnosis of hepatocellular carcinoma. Am J Surg Pathol 2012; 36: 710-715 [PMID: 22498821 DOI: 10.1097/ PAS.0b013e3182495c73]
96. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474 [PMID: 10484010 DOI: 10.1111/j.1572-0241. 1999.01377.x]
97. Hall AR, Dhillon AP, Green AC, Ferrell L, Crawford JM, Alves V, Balabaud C, Bhathal P, Bioulac-Sage P, Guido M, Hytiroglou P, Nakanuma Y, Paradis V, Quaglia A, Snover D, Theise N, Thung S, Tsui W, van Leeuwen DJ. Hepatic steatosis estimated microscopically versus digital image analysis. Liver Int 2013; 33: 926-935 [PMID: 23560780 DOI: 10.1111/liv. 12162]
98. Karlas T, Petroff D, Garnov N, Böhm S, Tenckhoff H, Wittekind C, Wiese M, Schiefke I, Linder N, Schaudinn A, Busse H, Kahn T, Mössner J, Berg T, Tröltzsch M, Keim V, Wiegand J. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One 2014; 9: e91987 [PMID: 24637477 DOI: 10.1371/journal. pone.0091987]
99. Schwimmer JB, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN, Lam J, Hooker JC, Hamilton G, Fontanesi J, Sirlin CB. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology 2015; 61: 1887-1895 [PMID: 25529941 DOI: 10.1002/ hep.27666]
100. Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5: 189-200 [PMID: 21476914 DOI: 10.1586/egh.11.21]
101. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steato- hepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219 [PMID: 12717402 DOI: 10.1053/ jhep.2003.50193]
102. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013; 59: 550-556 [PMID: 23665288 DOI: 10.1016/ j.jhep.2013.04.027]
103. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing- steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015; 62: 1148-1155 [PMID: 25477264 DOI: 10.1016/j.jhep.2014.11.034]
104. Matsuda Y, Takada A, Kanayama R, Takase S. Changes of hepatic microtubules and secretory proteins in human alcoholic liver disease. Pharmacol Biochem Behav 1983; 18 Suppl 1: 479-482 [PMID: 6634857]
105. Schaff Z, Lapis K. Fine structure of hepatocytes during the etiology of several common pathologies. J Electron Microsc Tech 1990; 14: 179-207 [PMID: 2187062 DOI: 10.1002/jemt.1060140302]
106. Gores GJ, Herman B, Lemasters JJ. Plasma membrane bleb formation and rupture: a common feature of hepatocellular injury. Hepatology 1990; 11: 690-698 [PMID: 2184116]
107. Caldwell S, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C, Pramoonjago P, Simmons W, Scruggs H, Rosenbaum N, Wilkinson T, Toms P, Argo CK, Al-Osaimi AM, Redick JA. Hepatocellular ballooning in NASH. J Hepatol 2010; 53: 719-723 [PMID: 20624660 DOI: 10.1016/j.jhep.2010.04.031]
108. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008; 48: 821-828 [PMID: 18329127 DOI: 10.1016/j.jhep.2008.01.026]
109. Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis 2016; 20: 293-312 [PMID: 27063270 DOI: 10.1016/ j.cld.2015.10.011]
110. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007; 43: 979-992 [PMID: 17291746 DOI: 10.1016/j.ejca.2007.01.004]
111. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300-4308 [PMID: 18666317 DOI: 10.3748/wjg.14.4300]
112. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140 [PMID: 12105842 DOI: 10.1053/gast.2002.34168]
113. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009; 115: 5651-5661 [PMID: 19834957 DOI: 10.1002/cncr.24687]
114. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008; 132: 1761-1766 [PMID: 18976012 DOI: 10.1043/1543-2165-132.11.1761]
115. Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010; 16: 1436-1441 [PMID: 20333782 DOI: 10.3748/wjg.v16.i12.1436]
116. Salomao M, Remotti H, Vaughan R, Siegel AB, Lefkowitch JH, Moreira RK. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 2012; 43: 737-746 [PMID: 22018903 DOI: 10.1016/ j.humpath.2011.07.005]
117. Salomao M, Yu WM, Brown RS, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010; 34: 1630-1636 [PMID: 20975341 DOI: 10.1097/PAS.0b013e3181f31caa]
118. Jain D, Nayak NC, Kumaran V, Saigal S. Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India. Arch Pathol Lab Med 2013; 137: 961-966 [PMID: 23808468 DOI: 10.5858/arpa.2012-0048-OA]
119. Yeh MM, Liu Y, Torbenson M. Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study. Hum Pathol 2015; 46: 1769-1775 [PMID: 26410018 DOI: 10.1016/ j.humpath.2015.07.018]
120. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, Lavine JE. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42: 641-649 [PMID: 16116629 DOI: 10.1002/hep.20842]
121. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 15915461 DOI: 10.1002/ hep.20701]
122. Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014; 60: 565-575 [PMID: 24753132 DOI: 10.1002/hep.27173]
123. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Goodman Z. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53: 1874-1882 [PMID: 21360720 DOI: 10.1002/hep.24268]
124. Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, Tordjman J, Clement K. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56: 1751-1759 [PMID: 22707395 DOI: 10.1002/ hep.25889]
125. Hjelkrem M, Stauch C, Shaw J, Harrison SA. Validation of the non-alcoholic fatty liver disease activity score. Aliment Pharmacol Ther 2011; 34: 214-218 [PMID: 21585409 DOI: 10.1111/j. 1365-2036.2011.04695.x]
126. Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11: 860-868 [PMID: 17492335 DOI: 10.1007/s11605-007-0149-4]
127. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94: 274-286 [PMID: 17315288 DOI: 10.1002/bjs.5719]
128. Gentilucci UV, Santini D, Vincenzi B, Fiori E, Picardi A, Tonini G. Chemotherapy-induced steatohepatitis in colorectal cancer patients. J Clin Oncol 2006; 24: 5467; author reply 5467-5468 [PMID: 17135651 DOI: 10.1200/jco.2006.08.1828]
129. Sakhuja P. Pathology of alcoholic liver disease, can it be differentiated from nonalcoholic steatohepatitis? World J Gastroenterol 2014; 20: 16474-16479 [PMID: 25469015 DOI: 10.3748/wjg.v20. i44.16474]
130. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol 2010; 105: 14-32; quiz 33 [PMID: 19904248 DOI: 10.1038/ajg.2009.593]
131. Bahirwani R, Reddy KR. Drug-induced liver injury due to cancer chemotherapeutic agents. Semin Liver Dis 2014; 34: 162-171 [PMID: 24879981 DOI: 10.1055/s-0034-1375957]
132. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333: 1118-1127 [PMID: 7565951 DOI: 10.1056/nejm199510263331706]
133. Amacher DE, Chalasani N. Drug-induced hepatic steatosis. Semin Liver Dis 2014; 34: 205-214 [PMID: 24879984 DOI: 10.1055/ s-0034-1375960]
134. Schumacher JD, Guo GL. Mechanistic review of drug-induced steatohepatitis. Toxicol Appl Pharmacol 2015; 289: 40-47 [PMID: 26344000 DOI: 10.1016/j.taap.2015.08.022]
135. Thomopoulos KC, Arvaniti V, Tsamantas AC, Dimitropoulou D, Gogos CA, Siagris D, Theocharis GJ, Labropoulou-Karatza C. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 2006; 18: 233-237 [PMID: 16462535]
136. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol 2011; 26: 1361-1367 [PMID: 21649726 DOI: 10.1111/ j.1440-1746.2011.06801.x]
137. Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, Nascimbeni F, Loria P. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol 2014; 20: 7089-7103 [PMID: 24966582 DOI: 10.3748/wjg.v20.i23.7089]
138. Vallet-Pichard A, Mallet V, Pol S. Nonalcoholic fatty liver disease and HIV infection. Semin Liver Dis 2012; 32: 158-166 [PMID: 22760655 DOI: 10.1055/s-0032-1316471]
139. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol 2004; 99: 1316-1320 [PMID: 15233671 DOI: 10.1111/j.1572-0241.2004.30444.x]
140. Yatsuji S, Hashimoto E, Kaneda H, Taniai M, Tokushige K, Shiratori K. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful? J Gastroenterol 2005; 40: 1130-1138 [PMID: 16378177 DOI: 10.1007/s00535-005-1711-z]
141. Hindi M, Levy C, Couto CA, Bejarano P, Mendes F. Primary biliary cirrhosis is more severe in overweight patients. J Clin Gastroenterol 2013; 47: e28-e32 [PMID: 23059407 DOI: 10.1097/ MCG.0b013e318261e659]
142. Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. World J Gastroenterol 2015; 21: 12989-12995 [PMID: 26675364 DOI: 10.3748/wjg.v21.i46.12989]
143. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007; 46: 999-1008 [PMID: 17188392 DOI: 10.1016/j.jhep.2006.10.019]
144. Kim JY, Song EH, Lee HJ, Oh YK, Choi KH, Yu DY, Park SI, Seong JK, Kim WH. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. J Mol Biol 2010; 397: 917-931 [PMID: 20156456 DOI: 10.1016/ j.jmb.2010.02.016]
145. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of nonalcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974 [PMID: 20581244 DOI: 10.1136/gut.2009.205088]
146. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873 [PMID: 17006923 DOI: 10.1002/hep.21327]
147. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-138 [PMID: 15629518 DOI: 10.1016/j.jhep.2004.09.012]
148. Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002; 55: 689-692 [PMID: 12195000]
149. Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820-826 [PMID: 15382171 DOI: 10.1002/hep.20410]
150. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-2047 [PMID: 14499785 DOI: 10.1111/j.1572-0241.2003.07659.x]
151. Hui AY, Wong VW, Chan HL, Liew CT, Chan JL, Chan FK, Sung JJ. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005; 21: 407-413 [PMID: 15709991 DOI: 10.1111/j.1365-2036.2005.02334.x]
152. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle- aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]
153. Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013; 95: 755-760 [PMID: 23370710 DOI: 10.1097/TP.0b013e31827afb3a]
154. Agopian VG, Kaldas FM, Hong JC, Whittaker M, Holt C, Rana A, Zarrinpar A, Petrowsky H, Farmer D, Yersiz H, Xia V, Hiatt JR, Busuttil RW. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 2012; 256: 624-633 [PMID: 22964732 DOI: 10.1097/SLA.0b013e31826b4b7e]
155. Yang JD, Abdelmalek MF, Pang H, Guy CD, Smith AD, Diehl AM, Suzuki A. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014; 59: 1406-1414 [PMID: 24123276 DOI: 10.1002/hep.26761]
156. Klair JS, Yang JD, Abdelmalek MF, Guy CD, Gill RM, Yates K, Unalp-Arida A, Lavine JE, Clark JM, Diehl AM, Suzuki A. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology 2016; 64: 85-91 [PMID: 26919573 DOI: 10.1002/hep.28514]
157. Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F, Louden C, Tio F, Cusi K. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology 2011; 54: 837-845 [PMID: 21674556 DOI: 10.1002/hep.24483]
158. Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014; 5: 4309 [PMID: 24978903 DOI: 10.1038/ncomms5309]
159. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-1217 [PMID: 20373368 DOI: 10.1002/hep.23622]
160. Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, Goodman Z, Younossi Z. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1224-1229, 1229.e1-2 [PMID: 19559819 DOI: 10.1016/j.cgh.2009.06.007]
161. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired- biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-654.e1-9; quiz e39-40 [PMID: 24768810 DOI: 10.1016/j.cgh.2014.04.014]
162. de Freitas AC, Campos AC, Coelho JC. The impact of bariatric surgery on nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2008; 11: 267-274 [PMID: 18403923 DOI: 10.1097/ MCO.0b013e3282fbd33f]
163. Verna EC, Berk PD. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. Semin Liver Dis 2008; 28: 407-426 [PMID: 18956297 DOI: 10.1055/ s-0028-1091985]
164. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, Pigeyre M, Verkindt H, Dharancy S, Louvet A, Romon M, Pattou F. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532-540 [PMID: 19409898 DOI: 10.1053/j.gastro.2009.04.052]
165. Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol 1992; 87: 775-779 [PMID: 1590319]
166. Rabl C, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis 2012; 32: 80-91 [PMID: 22418890 DOI: 10.1055/s-0032-1306428]
167. Wieser V, Adolph TE, Enrich B, Moser P, Moschen AR, Tilg H. Weight loss induced by bariatric surgery restores adipose tissue PNPLA3 expression. Liver Int 2017; 37: 299-306 [PMID: 27514759 DOI: 10.1111/liv. 13222]
168. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres- Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015; 149: 367-378.e5; quiz e14-5 [PMID: 25865049 DOI: 10.1053/j.gastro.2015.04.005]
169. Cho JY, Chung TH, Lim KM, Park HJ, Jang JM. The impact of weight changes on nonalcoholic Fatty liver disease in adult men with normal weight. Korean J Fam Med 2014; 35: 243-250 [PMID: 25309705 DOI: 10.4082/kjfm.2014.35.5.243]
170. You DM, Volk CG, Philo L, Partridge BJ. Weight loss outcomes after liver biopsy in patients with nonalcoholic fatty liver disease. Dig Liver Dis 2014; 46: 1136-1137 [PMID: 25241133 DOI: 10.1016/j.dld.2014.08.042]
171. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, Aslam T, Patanwala I, Gaggar S, Cole M, Sumpter K, Stewart S, Rose J, Hudson M, Manas D, Reeves HL. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60: 110-117 [PMID: 23978719 DOI: 10.1016/ j.jhep.2013.08.011]
172. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208 [PMID: 20141834 DOI: 10.1016/j.cell.2009.12.052]
173. Zámbó V, Simon-Szabó L, Szelényi P, Kereszturi E, Bánhegyi G, Csala M. Lipotoxicity in the liver. World J Hepatol 2013; 5: 550-557 [PMID: 24179614 DOI: 10.4254/wjh.v5.i10.550]
174. Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, May SB, Kramer JR, Richardson PA, Davila JA. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015; 13: 594-601.e1 [PMID: 25148760 DOI: 10.1016/ j.cgh.2014.08.013]
175. Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H. Large-scale longterm follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012; 107: 253-261 [PMID: 22008893 DOI: 10.1038/ajg.2011.327]
176. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to nonalcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248-254 [PMID: 19032450 DOI: 10.1111/j.1440-1746.2008.05640.x]
177. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609 [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001]
178. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33 [PMID: 16799979 DOI: 10.1002/ hep.21223]
179. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649 [PMID: 21039302 DOI: 10.3109/0785 3890.2010.518623]
180. Afonso MB, Rodrigues PM, Simão AL, Castro RE. Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J Clin Med 2016; 5: pii: E30 [PMID: 26950158 DOI: 10.3390/jcm5030030]
181. Ban LA, Shackel NA, McLennan SV. Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2016; 17: 376 [PMID: 26985892 DOI: 10.3390/ijms17030376]
182. Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut 2017; 66: 180-190 [PMID: 27646933 DOI: 10.1136/gutjnl-2016-312431]
183. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yeşilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-544 [PMID: 14987322]
184. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894 [PMID: 11567710]
185. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, Hoofnagle JH. Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29: 172-182 [PMID: 18945255 DOI: 10.11n/j.1365-2036.2008.03869.x]
186. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-2490 [PMID: 14638353 DOI: 10.1111/j.1572-0241.2003. 08699.x]
187. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-1543 [PMID: 17162245 DOI: 10.1016/j.cgh.2006.09.025]
188. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46 [PMID: 15537682]
189. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-1556 [PMID: 21990298 DOI: 10.1001/jama.2011.1437]
190. Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother 2016; 17: 1937-1946 [PMID: 27564402 DOI: 10.1080/14656566.2 016.1225727]
191. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859-871 [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044]